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Abstract
Transgender people continue to be at high-risk for HIV acquisition, but little is known about the characteristics of their sexual partners.
To address this gap, we examined sociodemographic and sexual characteristics of cisgender men who have sex with men (MSM) on
pre-exposure prophylaxis (PrEP) reporting transgender sexual partners.
A cohort of 392 MSM in southern California in a randomized clinical trial for PrEP adherence were followed from 2013 to 2016.
Multivariable generalized estimating equation and logistic models identified characteristics of MSM reporting transgender sexual
partners and PrEP adherence.
Only 14 (4%) MSM reported having transgender sexual partners. MSMwere more likely to report transgender partners if they were
African American, had incident chlamydia, reported injection drug-using sexual partners, or received items for sex. Most associations
remained significant in the multivariable model: African American (adjusted odds ratio [AOR] 11.20, P= .01), incident chlamydia (AOR
3.71, P= .04), and receiving items for sex (AOR 5.29, P= .04). There were no significant differences in PrEP adherence betweenMSM
reporting transgender partners and their counterpart.
MSM who report transgender sexual partners share characteristics associated with individuals with high HIV prevalence.
Identifying this group distinct from larger cohorts of MSM could offer new HIV prevention opportunities for this group of MSM and the
transgender community.
Abbreviations: AOR= adjusted odds ratio, CASI= computer assisted self-interviewing, GEE= generalized estimating equations,
IDU = injection drug use, IQR = interquartile range, MSM = men who have sex with men, OR = odds ratio, PrEP = pre-exposure
prophylaxis, RPR = rapid plasma regain, STI = sexually transmitted infection, TAPIR = Text Messaging to Improve Adherence to
PrEP in Risky MSM, TFV-DP = tenofovir diphosphate, TGM = transgender men, TGW = transgender women.
Keywords: female to male, HIV risk factors, male to female, men who have sex with men, PrEP, transgenderEditor: Giuseppe Lapadula.
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11. Introduction
While overall incidence of HIV in the United States (US) have
been on a decline, cisgender men who have sex with men (MSM)
and transgender people, individuals whose gender identity and/or
expression is different from their sex assigned at birth,[1] continue
to be at high risk of HIV acquisition. In 2016, MSM aged 13
years and older accounted for 67% of new HIV diagnoses in the
United States.[2] Transgender people had 3 times the national
average of newHIV diagnosis in 2015, with over 5 times as many
HIV diagnosis in transgender women (TGW) than in transgender
men (TGM).[3] A recent systemic review and meta-analysis
among US transgender population, estimated to comprise of 1
million adults,[4] reported that the prevalence of lab confirmed
HIV infection was 9% (95% CI 6–14%), whereas self-reported
HIV infection was 16% (95% CI 12–21%).[5]
MSM[6] and transgender people[7] have both self-identified
cisgender and transgender sexual partners, adding complexity in
identifying risk factors based on sexual partner types. Individual
risks of HIV acquisition for MSM have been associated with
condomless anal receptive sex, high frequency of male partners,
injection drug use (IDU), high viral load in index partner, and
amphetamine type stimulants.[8] Individual risks of HIV
acquisition for transgender people are similar to those of
MSM and have been associated with condomless anal sex,
multiple casual partner, sex work, IDU, mental health concerns,
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limited, but has found TGM often identify as “gay” and also
engage in highHIV acquisition risk behaviors including both anal
and vaginal intercourse.[11] However, individual risk factors are
insufficient to understand the network-level transmission be-
tween MSM and transgender people. Furthermore, TGW report
different risk behaviors in the context of primary and concurrent
partners outside their primary relationship.[12] The intersection
of social and gender identities and different contextual risk
between transgender people and their sexual partners make it
difficult to appropriately target and design HIV interventions and
prevention strategies.[13]
Current risks associated with sexual partners of transgender
people include condomless sex and substance use, including
poppers and methamphetamine.[12,14] More specifically, African
AmericanMSMwith transgender partners are 3 times more likely
to have at least 5 new recent sexual partners and twice as likely to
have condomless sexual acts.[15] African American MSM with
transgender partners were also found to be older, have a history
of incarceration and identified their sexual orientation as “other
than homosexual”.[15] To further understand the characteristics
distinguishing sexual partners of transgender people, we used
data from a cohort of high-risk HIV-uninfected cis-MSM
enrolled in a pre-exposure prophylaxis (PrEP) adherence trial
to identify risk factors associated with having a transgender
partner. We hypothesized that cis-MSM reporting a transgender
partner over the 48-week study would be associated with higher
risk behaviors compared with their counterparts.
2. Methods
2.1. Design and setting
This study is a secondary analysis of 392 cis-MSM (hereon
referred to as MSM) at increased risk of HIV followed for 48
weeks from February 2013 through March 2016 as part of the
Text Messaging to Improve Adherence to PrEP in Risky MSM
(TAPIR) study in 4 Southern California medical centers located in
SanDiego, Los Angeles, and Long Beach. Design and eligibility of
the TAPIR study is described in detail elsewhere.[16] Data for this
analysis includes sociodemographic characteristics collected at
baseline; sexual and risk behavior characteristics reported at
weeks 0, 4, 12, 24, 36, and 48 using a computer assisted self-
interviewing (CASI) survey; and laboratory sexually transmitted
infection (STI) testing at baseline and every 12 to –24 weeks.
2.2. Variables of interest
The longitudinal dependent variable of having a transgender
sexual partner (TGW and/or TGM) was captured by asking
participants in the sexual risk questionnaire, “In the past 3
months who did you have sex with?” Those who responded to
either “male to female transgender” or “female to male
transgender” were considered to have a transgender sexual
partner. Ever having a transgender sexual partner was defined as
having reported a transgender partner at least once over the 48
weeks of CASI assessments.
Assessment of independent variables included socioeconomic
status (e.g., age, race/ethnicity, annual income, and education
level), drug use (e.g., alcohol, marijuana, poppers, dissociatives,
hallucinogens, cocaine, and methamphetamine), and sexual risk
behavior in the past 3 months, which was captured from
structured CASI questionnaires. Participants indicating a male2and/or transgender sex partner in the past 3 months were also
asked for:(1) Number of male partners;
(2) Engagement in anal insertive or anal receptive sex and
frequency of condom use for anal insertive or anal receptive
sex;(3) Receipt of money, drugs or items for sex;
(4) Partner HIV status (positive or unknown); and
(5) Partner who is an IDU.
Response options were categorized to best accommodate the
limited number of outcomes.2.3. Biomedical factors
STI screening assessments were conducted for syphilis using
serum rapid plasma regain (RPR) and confirmatory treponemal
test, and for chlamydia and gonorrhea of urine, pharynx and
rectum using Hologic Aptima Combo2. Lab results for
gonorrhea and chlamydia were dichotomized for a positive
rectal, urine, or pharyngeal test and for new syphilis for a positive
RPR upon clinical verification. PrEP adherence was measured by
dried blood spot tenofovir diphosphate (TFV-DP) concentrations
(fmol/punch) at weeks 12 and 48 using liquid chromatography-
tandem mass spectrometry assay validated for determination of
TFV in human red blood cells.[17] Adherence was considered
adequate if TFV-DP levels were >719fmol/punch (≥4 doses/
week) and perfect if >1246fmol/punch (7 doses/week) with
thresholds verified previously.[17]2.4. Statistical analysis
Baseline characteristicswere summarizedbyMSMever reporting a
transgender partner using simple frequencies. Pearson’s chi-
squared compared differences in frequencies and proportions
for categorical variables and Fisher’s exact method when cell
frequencies were <5. As the TAPIR study was prospective and
sexual behavior may be non-independent within participants over
time, marginal risk factors associatedwith reporting a transgender
partner were estimated using a generalized estimating equations
(GEE) under a binomial distribution with a logit link model.
Robust estimates of standard errors were applied based on the
sandwich estimator with an exchangeable working correlation
matrix for valid estimates. Missing data assumption of missing
completely at randomwas tested using Little’sX2 test. As PrEPwas
initiated at enrollment, the GEEmodel included data fromweeks 4
to 48 adjusted for race/ethnicity, incident chlamydia, IDU sex
partner, and receiving items for sex selected based on significance
of P< .05 on the univariate model. For analytical purposes,
number of male sexual partners was square root transformed to
adjust for skewness and ease of interpretability. Association
between PrEP adherence and reporting a transgender partner was
modeled using logistic regression adjusted for race/ethnicity,
education, receipt of money, drugs or items for sex, and sex with
HIV unknown, positive or IDU partner, selected a priori. Data
management and statistical analysis was conducted using STATA/
SE 15.1, StataCorp LP, College Station, TX.2.5. Ethics approval and consent to participate
The main TAPIR study was approved and performed as per
regulations by University of California San Diego Human
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Institute at Harbor-UCLA Medical Center Institutional Review
Board and University of Southern California Office for the
Protection of Research Subjects. The study was registered with
ClinicalTrials.gov (NCT01761643) on January 2013 and
explained to all volunteers including purpose, procedures and
risks and benefits of participating before seeking a written
informed consent.
3. Results
3.1. MSM characteristics at baseline
The median age of 392 participants was 33 years (interquartile
range [IQR]: 28–41) with the majority being White (50%) and
Hispanic (30%), with fewer African American and Asian, multi,
or other race. AmongMSM ever reporting a transgender partner,
43% (6 of 14) were African American compared to only 10% (38
of 378) of MSM who never reported a transgender partner
(P= .001). Sixty-four percent (9 of 14) of MSM earned an annual
income of at least $24,000 and had some college or higher
education. Seventy-two percent (10 of 14) used some drugs at
baseline, alcohol was the most popular (64%). Twenty-one
percent (3 of 14) of participants had a STI (gonorrhea, chlamydia,
and/or syphilis) at baseline. There were no significant differences
in age, income, education, drug use, and STI between MSM
reporting transgender partners compared with MSM never
reporting transgender partners at baseline. MSM reporting a
transgender partner were more likely to have sex partners who
reported IDU (36% vs 13%, P= .02) or of unknown HIV status
(86% vs 55%, P= .03) compared to those with no transgender
partners (Table 1).3.2. MSM characteristics over time
Of 392 MSM included in this study, 14 (4%) reported having at
least 1 transgender sexual partner in the last 3 months over the 48
weeks study period. Nine MSM reported having only TGW as
sexual partners, 3 reported having only TGM sexual partner, and
2 reported both TGW and TGM as sexual partners. In univariate
analysis, MSM who were African American and Asian/multi/
other MSM had higher odds of reporting a transgender partner
(Table 2). Sexual risk factors associated with reporting a
transgender partner were incident chlamydia (odds ratio [OR]
OR 3.41, P= .04), engaging with an IDU sex partner (OR 4.67,
P= .01) and receiving money or other items for sex (OR 6.77,
P= .001). Controlling for confounders, African American
(adjusted odds ratio [AOR] 11.20, P= .01) MSM were more
likely to report transgender partners comparedwithWhiteMSM.
MSM with incident chlamydia (AOR: 3.71, P= .04) and
receiving items in exchange for sex (AOR 5.29, P= .04) remained
significant in the adjusted model and were more likely to report
transgender partners. Having a sex partner who used injection
drugs was not significant in the adjusted model.
3.3. PrEP adherence
Adherence to PrEP at week 12 was measured for 355
participants, 37 participants, including 4 MSMwith transgender
partners did not have any adherence results. Among 355
participants with complete results, 319 (90%) had adequate or
perfect adherence (Table 3). Seventy percent (7 of 10) of MSM
reporting transgender partners had adequate/perfect adherence3compared with 90% (309 of 345) ofMSMwithout a transgender
partner (OR 0.27, P= .06). Similarly, adherence levels at week 48
between the 2 groups showed non-significant results.4. Discussion
In our cohort of HIV-negative MSM on PrEP in southern
California, several factors were associated with having a
transgender sexual partner including African American race,
incident chlamydia infection, and having partners engaging in
highHIV risk behaviors such as IDU and receipt of money, drugs,
or items in exchange for sex. We found no difference in PrEP
adherence between those reporting transgender partners and
those without transgender partners.
Given the high rates of new HIV infection among African
AmericanMSM,[18–20] our finding that AfricanAmericanMSM
were more likely to report having a transgender partner
compared toWhiteMSM is consistent with there being a higher
risk sexual network for transgender people. Previous work
examining sexual partner characteristics similarly found that
HIV-positive partners of TGW were more likely to be African
American and identify as MSM.[21] In a 2014 San Francisco
study ofMSMandTGW,[22] AfricanAmericanMSMandTGW
were overall more similar in socioeconomic status compared
withWhite MSM, suggesting race/ethnicity and socio-econom-
ic status may be driving forces in establishing this sexual
network. Looking at HIV diagnoses among African American
MSM by age group, there was an overall decrease in HIV
diagnoses in all age groups except for 25–34-year category
which showed a 40% increase between 2010 and 2016.[23]
Interestingly, according to a 2010HPTN cohort, AfricanMSM
most likely to report a transgender partner were ≥46 years of
age (AOR 1.69, 95% CI 1.22–2.35).[15] It appears that
although young African American MSM experience the
greatest burden of the HIV epidemic, older African American
MSM with stable HIV diagnoses are more likely to report a
transgender partner.[23]
In addition to sociodemographic characteristics, transgender
people have reported high risk behaviors including condomless
anal receptive sex, STIs, and sex work in previous and current
studies.[7,24–27] We found similar trends in our cohort of MSM
including chlamydia infections, having sex partners who use
injection drugs, and receiving money or other items in exchange
for sex. Despite the relatively small numbers that may have
affected these aforementioned factors, chlamydia infections and
receiving money or other items in exchange for sex remained
significant in the adjusted model. Engaging in exchange sex has
consistently been reported as more frequent among transgender
people.[21,28,29] MSM on PrEP in this study with transgender
partners also share this high-risk behavior. Molecular epidemi-
ology on the HIV-1 transmission network of TGW using genetic
sequencing show TGW to cluster with other TGW and cis-men,
further suggesting high risk activities and partners are shared
between these groups.[30] Shared risk behaviors make it
imperative to target both transgender people and their MSM
partners separate from larger cohorts of MSM as part of the
sexual network that facilitate transmission between these 2 risk
groups. However, identifying MSM who have transgender
partners is challenging due to discordance between men’s sexual
identity and sexual behavior[31]; MSM who report TGM as
sexual partners may not identify as MSM. In a cohort of African
American MSM, 90% with transgender partners did not identify
Table 1
Demographic and behavioral characteristic of HIV-uninfected cis-MSM at baseline.
Transgender sexual partner ever Transgender sexual partner ever
No (N=378) Yes (N=14)
P
No (N=378) Yes (N=14)
Pn %
∗
n %
∗
n %
∗
n %
∗
Demographics
Race/ethnicity .001 Education .21
White 194 51 2 14 High school or less 31 8 3 21
Hispanic 112 30 4 29 College 268 71 9 64
Asian/multi/other 34 9 2 14 Advanced degree 79 21 2 14
African American 38 10 6 43
Age .37 Annual income .63
19–29 121 32 6 43 <$24,000 79 21 4 28
30–39 152 40 3 21 ≥ $24,000 238 63 9 64
40+ 105 28 5 36
Drug use
Any drug use 1.0 Illegal activity for drugs 1.00
No 100 27 4 29 No 347 92 13 93
Yes 277 73 10 72 Yes 30 8 1 7
Alcohol 1.00 Poppers .28
No 65 17 2 14 No 180 48 9 64
Yes 312 83 12 86 Yes 197 52 5 36
Marijuana .28 Multiple drug use† .12
No 198 52 5 36 No 138 37 8 57
Yes 179 47 9 64 Yes 239 63 6 43
Sexual risk behavior
No. male sex partners, median (IQR) 6 3, 10 12 4, 25 .09 Douching/enema .40
No 122 32 6 43
Yes 253 67 8 57
AI sex with male partner 1.00 AR sex with male partner .72
No 46 12 1 7 No 85 23 3 21
Yes 321 85 10 71 Yes 284 75 8 57
Condom use for AI sex .84 Condom use for AR sex 1.00
Never 61 16 1 7 Never 43 11 1 7
Rarely/sometimes 161 43 5 36 Rarely/sometimes 120 32 3 21
Often/always 100 27 4 29 Often/always 120 32 4 29
Buy sex‡ .53 Sell sexx .35
No 359 95 13 93 No 346 91 12 86
Yes 19 5 1 7 Yes 32 9 2 14
Method for meeting sexual partner .27 Sex partner – HIV status unknown .027
None 43 11 1 7 No 170 45 2 14
Online app 122 32 2 14 Yes 208 55 12 86
Bathhouse/bar/combo 210 56 11 79
Sex partner – injection drug use .017 Sex partner – HIV positive .78
No 328 87 9 64 No 123 33 5 36
Yes 50 13 5 36 Yes 255 67 9 64
Sexually transmitted infections
Any STI (GC/CT/Syp) 1.00 Gonorrhea 1.00
No 300 80 11 79 No 338 89 13 93
Yes 77 20 3 21 Yes 40 11 1 7
Syphilis 1.00 Chlamydia .40
No 376 99 14 100 No 332 88 11 79
Yes 1 1 0 0 Yes 46 12 3 21
AI= anal insertive, AR= anal Receptive, CT=chlamydia, GC=gonorrhea, IQR= interquartile range, MSM=men who have sex with men, STI= sexually transmitted infection, Syp= syphilis.
∗
Percent may not total 100 because of missing data/rounding.
† Any use of poppers, methamphetamine, dissociatives, hallucinogens, and/or cocaine.
‡ Give money/items/drugs for sex.
x Receive money/items/drugs for sex.
Hassan et al. Medicine (2019) 98:50 Medicineas homosexual[15] and MSM identifying as bisexual receive
stigmatizing or negative attitude, making it less attractive to
disclose gender identity.[32] Continuing efforts to minimize
disparities in social attitudes towards bisexual men and women4while affording participants to report non-binary gender and
sexual identities would benefit future research.
Our study specifically identified risk behaviors for MSM with
transgender partners on PrEP, which reduces HIV transmission
Table 2
Adjusted/unadjusted odds of reporting a transgender sexual partner among HIV-uninfected cis-MSM on PrEP.
Reported ≥1 transgender sexual partner
Univariate Multivariate
Characteristic OR 95% CI P AOR
∗
95% CI P
Demographics
Age
19–29 Ref – –
30–39 0.40 0.09–1.85 0.240
40+ 1.01 0.26–3.97 0.989
Race
White Ref – – Ref – –
Hispanic 4.16 0.66–26.28 0.130 3.13 0.53–18.37 0.207
Asian/multi/other 9.09 1.21–68.07 0.032 7.10 0.62–81.65 0.116
African American 13.69 2.77–70.37 0.002 11.20 1.65–76.14 0.014
Annual income
<$24,000 Ref – –
≥ $24,000 0.55 0.15–1.95 0.352
Education
High school or less 2.58 0.51–13.06 0.252
Some college – – –
Some advanced degree 0.63 0.13–3.03 0.568
Drug and STI
Multiple drug use†
No Ref – –
Yes 0.64 0.19–2.10 0.459
Incident chlamydia‡
No Ref – – Ref – –
Yes 3.41 1.06–10.97 0.040 3.71 1.06–12.98 0.040
Incident gonorrhea‡
No – – –
Yes 3.27 0.76–14.12 0.113
Sexual risk behavior
Sex partner – injection drug use
No Ref – – Ref – –
Yes 4.67 1.39–15.71 0.013 2.78 0.59–13.09 0.195
Sex partner – HIV status unknown
No Ref – –
Yes 1.99 0.67–5.92 0.212
Receive money/items/drugs for sex
No Ref – – Ref – –
Yes 6.77 2.14–21.34 0.001 5.29 1.04–26.87 0.045
Method of meeting partner
None Ref – –
Internet/mobile app only 1.11 0.24–5.15 0.891
Bath house/bar/combo 1.61 0.44–5.81 0.471
Number of male sex partnersx 1.28 0.98–1.66 0.067
Condom use for anal insertive sex
Never 3.14 0.61–16.14 0.172
Rarely/sometimes 0.66 0.09–4.80 0.682
Often/always Ref – –
Condom use for anal receptive sex
Never 1.60 0.27–9.61 0.606
Rarely/sometimes 0.34 0.03–3.74 0.377
Often/always Ref – –
AOR=adjusted odds ratio, CI= confidence interval, IDU= injection drug use, MSM=men who have sex with men, OR= cdds ratio, PrEP=pre-exposure prophylaxis.
∗
Adjusted for race/ethnicity, incident chlamydia, sex with an IDU partner and receipt of money/items/drugs for sex.
† Any use of poppers, methamphetamine, dissociatives, hallucinogens, and/or cocaine.
‡ Urethral, thoracic and/or rectal.
x Square root transformed.
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social interactions and adherence patterns.[35] We did not find
any differences in adherence to PrEP among MSM with
transgender partners compared with MSM not reporting5transgender partners. There has been discrepancy in reporting
of risk behaviors between studies based in clinics versus clinical
trials. Some clinic based studies suggest risky sexual practices
such as condomless sex may be higher in populations on
Table 3
Adjusted/unadjusted odds of PrEP adherence for HIV-uninfected cis-MSM reporting ≥1 transgender sexual partner.
Adequate or perfect adherence
∗
No (N=39) Yes (N=319) Tot‡ (N=355)
Univariate Multivariate
OR 95% CI P AOR† 95% CI P
Transgender sexual partner
No 36 309 345 Ref – – Ref – –
Yes 3 7 10 0.27 0.07–1.10 0.067 0.39 0.08–1.71 0.210
AOR= adjusted odds ratio, CI= confidence interval, MSM=men who have sex with men, OR= odds ratio, PrEP=pre-exposure prophylaxis, TFV-DP= tenofovir diphosphate.
∗
Adequate or perfect adherence is measured by TFV-DP levels >719 fmol/punch (≥4 doses/week).
† Adjusted for race/ethnicity, education, receipt of money/items/drugs for sex, and sex with HIV positive, unknown or injection drug using partner.
‡Missing adherence results for 37 (9%) participants.
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than prior clinical trials of PrEP that did not show such
evidence.[33,35] In our cohort, frequency of condom use for
insertive or receptive anal sex were not associated with having
transgender partners. Our results did not identify a significant
difference between number of cis-male partners over 48 weeks
and MSM with and without transgender partners, suggesting
MSM on PrEP overall do not engage any differently with other
cisgender male partners regardless of reporting a transgender
partner. This finding is different than HPTN cohort where
African American MSM with transgender partners had ≥5 new
partners (AOR 3.67, 95% CI 2.98–4.97) in the last 6 months
before data collection.[15] A reason for the differences may be due
to comparing behavior over time versus at baseline, and a
population of primarily White and Hispanic MSM on PrEP
versus only African American MSM who are either HIV positive
or negative in the HPTN trial. Despite this difference, our results
also show MSM with transgender partners may play a critical
role in the transmission between the 2 groups.[12,15,30]
Our analysis has several limitations. As we performed a
secondary analysis of a PrEP trial, only the main study was
sufficiently powered and only a small number ofMSM reported a
transgender partner, restricting confounders to adjust for in the
multivariable model and conducting sub-group analysis between
TGW and TGM. Our questionnaire did not explicitly distinguish
between casual versus primary sexual partners, however, 69% of
the time the method to meet partner was through internet, mobile
applications, bath house, bar, sex party or other, suggesting this
cohort were possibly engaging more with casual sexual partners.
Our results may not be generalizable to all MSM in southern
California, since MSM enrolled in the main study were at
increased risk for HIV and other STI than the general MSM
population. Moreover, as cisgender males reporting TGW or
TGMpartners may not identify as either gay orMSM, our results
do not address this gap in gender identity and may not be
generalizable to all MSM. Finally, as PrEP was provided for free
to participants in the main study, we are unsure how interruption
in PrEP uptake beyond the study period may affect these
behaviors. Despite these limitations, our study used longitudinal
data to study behavior of high-riskMSMon PrEP identifying risk
behaviors that may change over time and sociodemographic
factors associated with having a transgender partner.
Our results showMSMwith transgender partners have higher
HIV risk behaviors compared with their non-transgender
reporting counterparts. This finding reinforces the need to
address the sexual networks of transgender people that include
high-risk MSM and drivers that determine sexual partner6interactions such as the role of sex work, socioeconomic
status, and social interactions. A comprehensive approach
to HIV prevention in the transgender community incorporating
structural interventions in health and human rights, education
and economic opportunities to reduce the need for survival sex,
along with clinical preventive interventions may be more
beneficial and efficacious. Better understanding of this interaction
may help in the design of new interventions or adaptation of
existing strategies to meet the unique HIV prevention needs
for those at-risk of HIV acquisition in the transgender
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